This site is intended for Healthcare professionals only.

Insulin glargine 300 safe, effective in elders with Diabetes : SENIOR Trial

Insulin glargine 300 safe, effective in elders with Diabetes : SENIOR Trial

Safety and efficacy of insulin glargine 300 units/mL (Gla-300) in older adults with type 2 diabetes (T2D) is equivalent to that of  Gla-100, with a similarly low or lower risk of symptomatic hypoglycemia, according to a study published in the journal Diabetes Care.

Robert Ritzel, Städtisches Klinikum München GmbH in Munich, Germany, conducted the study to compare the efficacy and safety of Gla-300 with Gla-100 in older people (≥65 years old) with type 2 diabetes.

Insulin glargine (Lantus) is a long-acting basal insulin analog which is given once daily to help control the blood sugar level of those with diabetes.

The open-label, two-arm, parallel-group, multicenter phase 3b SENIOR trial enrolled ∼20% of participants aged ≥75 years.   A total of 1,014 participants were randomized 1:1 to Gla-300 or Gla-100, titrated to a fasting self-monitored plasma glucose of 5.0–7.2 mmol/L.

Read Also: Dulaglutide as effective as insulin glargine in diabetes with CKD: Lancet

Key Findings:

  • From baseline to week 26, the reductions in HbA1c were comparable for Gla-300 and Gla-100 in the overall population and for participants aged ≥75 years
  • Similar and low incidence and rates of confirmed or severe hypoglycemic events were reported between the groups, with lower rates of documented symptomatic hypoglycemia with Gla-300.
  • Compared with the overall population, the subgroup aged ≥75 years had a more apparent lower risk of hypoglycemia with Gla-300 versus Gla-100.
  • The annualized rates of documented symptomatic hypoglycemia were significantly lower with Gla-300 (Gla-300, 1.12 versus Gla-100, 2.71; rate ratio, 0.45).

Read Also: Oral insulin pill- the future of diabetes treatment is almost here

Based on the study, the authors concluded that efficacy and safety of Gla-300 were demonstrated in older people (≥65 years of age) with type 2 diabetes, with comparable reductions in HbA1c and similarly low or lower risk of documented symptomatic hypoglycemia versus Gla-100. A significant benefit of hypoglycemia reduction was seen in participants aged ≥75 years.

For further reference log on to

The following two tabs change content below.
Medha Baranwal

Medha Baranwal

Medha Baranwal joined Medical Dialogues as a Desk Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She can be contacted at Contact no. 011-43720751
Source: With inputs from Diabetes Care

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted